Developer docs
API playgroundTry for free, no card

Search company profiles

Unitaid

Full company profile

uuid003zc5w

Namestring
Unitaid
Legal namestring
Unitaid
Websiteurl
unitaid.org
Company typeenum
Private
Founded yearint
2006
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersLe Grand-saconnex, Switzerland
HQ citystring
Le Grand-saconnex
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
global health financing, health product access, market shaping investments, innovative health partnerships, public health grants
Industry6 codes
PRIMARYHLAJAKAC
Global Health Financing Mechanisms
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAKAA
Multilateral Global Health Agencies (UN/IFIs)
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAKAL
Global Health Supply Chain & Procurement Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAKAF
Disease-Specific Global Programs (HIV/TB/Malaria/NTDs)
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAOAC
Global Health Financing Mechanisms & Pooled Funds
SECONDARYBPADAIAI
Health Supply Chain, Procurement & Access to Medicines
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services81321
SIC code1 code
  • Services-Social Services8300
Product category
Global Health Financing and Market Shaping
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Grants and Donations
TypeLicensing Royalties
Description

Unitaid receives financial investments from governments (Brazil, Canada, Chile, France, Japan, Norway, Portugal, Republic of Korea, Spain, United Kingdom), the European Union, Gates Foundation, Wellcome, and WHO Foundation. Founded in 2006 by Brazil, Chile, France, Norway and the United Kingdom.

unitaid.org
2Innovative Financing
TypeManaged Services
Description

Uses innovative financing solutions like volume guarantees to lower prices for health products and help get them to market. Building on legacy of successful innovative health financing including air levy mechanisms.

unitaid.org
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure, Technology or R&D
Pricing details3 tiers
1Lenacapavir generic version - approximately £30 per person per year
ModelUnit PricingBilling cadenceAnnual
Notes

Ceiling price of approximately £30 per person per year for quality-assured generic versions of lenacapavir, secured by Unitaid and Elton John AIDS Foundation for adolescent girls and young women in sub-Saharan Africa.

independent.co.uk
2Lenacapavir generic version - $40 per person annually
ModelUnit PricingBilling cadenceAnnual
Notes

$40 per person annually for 120 low- and middle-income countries through Dr. Reddy's Laboratories agreement coordinated by Unitaid, CHAI, and Wits RHI.

linkedin.com
3AirRay 20 X-ray system - discounted pricing for 138 LMICs
ModelUnit PricingBilling cadencePay-as-you-go
Notes

New pricing agreement with Poskom makes AirRay 20 ultraportable digital chest x-ray system available at discounted price to eligible programs in 138 low- and middle-income countries.

unitaid.org
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Unitaid finances and accelerates the development, introduction, and scale-up of innovative health products for HIV, tuberculosis, malaria, women's and children's health, and pandemic preparedness in low- and middle-income countries. It does this primarily through grants to implementing partners and market-shaping agreements (volume guarantees, ceiling prices, and technology partnerships) that drive down product costs and accelerate access for the people who need them most.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 390 million people benefit annually from Unitaid-supported health products
+5 more records
Product overview1 text field

Unitaid does not offer a single unified product but rather a portfolio of health product investments and initiatives across multiple disease areas. The organization works to accelerate access to innovative health products including: HIV prevention tools (lenacapavir twice-yearly injection), AI-powered diagnostic solutions (miLab CER for cervical cancer, AirRay 20 for TB screening), advanced HIV disease diagnostics (VITA CD4 Test), and novel testing approaches (pooled TB testing). Unitaid also supports regional manufacturing initiatives (MADE, MedSuRe Africa) to strengthen Africa's health product supply chains.

Product and service6 records
1MADE Program (Market Access and Diagnostic Equity)
CategoryRegional Manufacturing Program
Description

Unitaid-funded program that supports African manufacturers in developing and scaling diagnostic test production for regional and global markets, addressing the 70% of pharmaceuticals consumed in Africa that are imported.

2MedSuRe Africa Program
CategoryRegional Manufacturing Program
Description

Unitaid-funded program led by US Pharmacopeia (USP) that boosts regional production of essential medicines (including HIV, malaria, and postpartum hemorrhage treatments) and related quality testing infrastructure in Africa.

3Antimalarial Drug Resistance Initiative
CategoryDrug Resistance / Malaria Program
Description

A US$26.5 million Unitaid-funded initiative led with Jhpiego to curb rising antimalarial drug resistance in Africa.

4Cervical Cancer Elimination Call for Proposals (Secondary Prevention)
CategoryFunding Call for Proposals
Description

Unitaid funding call worth up to US$50 million for projects accelerating cervical cancer elimination through secondary prevention (screening and pre-cancer treatment) in low- and middle-income countries.

5Climate-Proof Health Products Funding Opportunity
CategoryClimate and Health Funding Opportunity
Description

A US$10 million Unitaid funding opportunity to generate evidence on how extreme heat and humidity affect the safety, quality and effectiveness of essential medicines and health products in LMICs.

6Pregnant Women's Care Expansion Initiative
CategoryMaternal Health Investment
Description

A US$52 million Unitaid investment to expand lifesaving care for pregnant women in Africa.

Scale indicator17 records

Each record includes

Type, Value, Description, Source

Partnership18 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-13
Description

Unitaid and Elton John AIDS Foundation advocating for urgent scale-up of lenacapavir for adolescent girls and young women in sub-Saharan Africa. Organizations secured ceiling price of approximately £30 per person per year for quality-assured generic versions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Unitaid, CHAI, and Wits RHI coordinated with Dr. Reddy's Laboratories to supply generic lenacapavir at $40 per person annually for 120 LMICs. Proof that early market-shaping can make affordability keep pace with innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Wits RHI collaborated with Unitaid and CHAI to coordinate lenacapavir generic pricing agreement with Dr. Reddy's Laboratories for 120 low- and middle-income countries.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

South Africa negotiating voluntary license agreement with Gilead Sciences with support from Unitaid and US Pharmacopeia. Lenacapavir use kicked off in South Africa and Brazil through Unitaid partnership with Wits RHI and Fiocruz.

5FIND
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-26
Description

Unitaid invested US$44 million since 2022 to advance TB diagnostics through partnerships with LSTM and FIND. Multi-country trial demonstrated pooled testing reducing TB testing costs by up to 65%.

unitaid.org
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-26
Description

Unitaid partnership with LSTM supporting TB diagnostics advancement as part of US$44 million investment since 2022.

7Noul Co. Ltd
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-01-06
Description

Noul debuted AI-powered cervical cancer diagnostic solution miLab CER at CES 2026. Unitaid recommended miLab CER for use in 2024 alongside solutions from Roche and Hologic.

prnewswire.com
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Support from Gates Foundation, Unitaid, and CHAI to expand manufacturing and global access to VITA CD4 test for managing advanced HIV disease. Initiative aims to accelerate regulatory approval and scale production.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-22
Description

Indian pharmaceutical company plan to produce generic versions of lenacapavir for $40 a year starting in 2027. Supported by Unitaid, Clinton Health Access Initiative, and Wits RHI to expand competitive generics ecosystem for the drug.

10Hetero Labs
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-24
Description

Gates Foundation partnership with Indian manufacturer Hetero Labs to produce low-cost generic version of lenacapavir at roughly $40 per patient per year, pending regulatory approval expected as early as 2027. Part of broader effort to accelerate affordable access to lenacapavir in LMICs.

gatesfoundation.org
11PATH
Strategic tierFlagshipTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-08-21
Description

PATH leads MADE program receiving US$ 11 million to support African companies in developing and scaling diagnostic test production for regional and global markets. Part of US$ 50 million flagship programs to strengthen Africa's regional manufacturing.

unitaid.org
12US Pharmacopeia (USP)
Strategic tierFlagshipTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-08-21
Description

USP leads MedSuRe Africa program receiving US$ 35.5 million to boost production of essential medicines including HIV, malaria, and postpartum hemorrhage treatments along with related quality testing infrastructure.

unitaid.org
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Medicines Patent Pool receives US$ 1.5 million for complementary work supporting the MedSuRe Africa flagship program for regional manufacturing.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-08-21
Description

Unitaid and Jhpiego launch US$26.5 million initiative to curb rising antimalarial drug resistance in Africa.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-20
Description

Unitaid and CHAI announced new pricing agreement with South Korean company Poskom to dramatically lower cost of AirRay 20 ultraportable digital chest x-ray system, making it available at discounted price to 138 LMICs.

16Japan / Nikkiso
Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Unitaid and Japan's Nikkiso partner with Kenya and Tanzania to build liquid medical oxygen facilities in East Africa through project with Japanese government committing funds.

unitaid.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2006-01-01
Description

Unitaid is a hosted partnership of WHO. Credibility and insight through WHO hosting. Operations administered in accordance with Unitaid's constitution and WHO rules. WHO uses evidence from Unitaid investments to create policy and guidance.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2006-01-01
Description

Collaboration with Global Fund to take products and best practices to scale. Global Fund is a major scale-up partner for Unitaid-supported interventions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Multilateral public-private partnership accelerating vaccine access in LMICs through innovative financing, market shaping, and Gavi-Advanced Market Commitments. Same financing/partnership DNA as Unitaid but focused on immunization.

TypeDirect peer
Description

Public-private partnership developing and delivering malaria treatments. Shares Unitaid's grant-funded, market-shaping approach and operates within the same global health ecosystem with overlapping donor and partner networks.

TypeOthers
Description

Major philanthropic funder of global health R&D and a current Unitaid donor. While not a direct competitor, Wellcome shapes the same funding and policy ecosystem and increasingly co-invests on issues like pandemic preparedness and climate-health.

TypeDirect peer
Description

Leads Unitaid's $11M MADE program for African diagnostic manufacturing and is a longstanding implementing partner across Unitaid's investment portfolio. Overlapping mission of accelerating health innovation in LMICs.

TypeDirect peer
Description

Not-for-profit R&D organization developing treatments for neglected diseases (sleeping sickness, leishmaniasis, Chagas disease, etc.) with funding from public and philanthropic donors. Closely mirrors Unitaid's grant-funded, partnership-driven model for access-oriented health R&D.

TypeDirect peer
Description

Operates as Unitaid's direct implementation co-pilot on market-shaping deals (lenacapavir generic pricing for 120 LMICs, AirRay 20 X-ray pricing for 138 LMICs). Both organizations negotiate volume guarantees and pooled procurement across the same disease portfolio.

7FIND (Foundation for Innovative New Diagnostics)
TypeDirect peer
Description

Strategic implementation partner for Unitaid's TB diagnostics portfolio ($44M joint investment since 2022) and pooled testing trials. Both organizations focus on introducing diagnostic innovations to LMIC public health systems.

TypeDirect peer
Description

Multilateral financing mechanism for the same three diseases Unitaid targets (HIV, TB, malaria), serving as Unitaid's primary scale-up partner to take innovative health products to LMICs. Operates with similar donor-funded, partnership-based model.

TypeDirect peer
Description

Founded by Unitaid in 2010 and still receiving direct Unitaid funding ($1.5M for MedSuRe Africa). MPP negotiates voluntary licenses for HIV, TB, and hepatitis C medicines in LMICs — a core enabler of Unitaid's generic pricing strategy.

TypeDirect peer
Description

Non-profit product development partnership advancing faster, cheaper TB regimens, working closely with Unitaid as a co-funder and implementer of TB innovations in LMICs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Unitaid

Global Health Financing and Market Shapingunitaid.org

Unitaid firmographics

Firmographics
Name
Unitaid
Legal name
Unitaid
Website
https://unitaid.org
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Unitaid industry classification

Industry
Product category
Global Health Financing and Market Shaping
NAICS
Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)
SIC
Services-Social Services (8300)
akta.pro industry
PRIMARYHLAJAKAC
Global Health Financing Mechanisms
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAKAA
Multilateral Global Health Agencies (UN/IFIs)
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAKAL
Global Health Supply Chain & Procurement Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAKAF
Disease-Specific Global Programs (HIV/TB/Malaria/NTDs)
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
SECONDARYHLAJAOAC
Global Health Financing Mechanisms & Pooled Funds
SECONDARYBPADAIAI
Health Supply Chain, Procurement & Access to Medicines

Keywords

  • Global health financing
  • Health product access
  • Market shaping investments
  • Innovative health partnerships
  • Public health grants

Where Unitaid is headquartered

Location

Headquarters

HQ city
Le Grand-saconnex
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Unitaid business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Supply Chain, Marketing or Sales, Infrastructure, Technology or R&D

Revenue model

  1. Grants and Donations: Unitaid receives financial investments from governments (Brazil, Canada, Chile, France, Japan, Norway, Portugal, Republic of Korea, Spain, United Kingdom), the European Union, Gates Foundation, Wellcome, and WHO Foundation. Founded in 2006 by Brazil, Chile, France, Norway and the United Kingdom.
  2. Innovative Financing: Uses innovative financing solutions like volume guarantees to lower prices for health products and help get them to market. Building on legacy of successful innovative health financing including air levy mechanisms.

Pricing tiers

ModelBillingPrice
Unit PricingAnnualLenacapavir generic version - approximately £30 per person per year
Unit PricingAnnualLenacapavir generic version - $40 per person annually
Unit PricingPay-as-you-goAirRay 20 X-ray system - discounted pricing for 138 LMICs

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Unitaid product offering

Product offering

Core offering

Unitaid finances and accelerates the development, introduction, and scale-up of innovative health products for HIV, tuberculosis, malaria, women's and children's health, and pandemic preparedness in low- and middle-income countries. It does this primarily through grants to implementing partners and market-shaping agreements (volume guarantees, ceiling prices, and technology partnerships) that drive down product costs and accelerate access for the people who need them most.

Product overview

Unitaid does not offer a single unified product but rather a portfolio of health product investments and initiatives across multiple disease areas. The organization works to accelerate access to innovative health products including: HIV prevention tools (lenacapavir twice-yearly injection), AI-powered diagnostic solutions (miLab CER for cervical cancer, AirRay 20 for TB screening), advanced HIV disease diagnostics (VITA CD4 Test), and novel testing approaches (pooled TB testing). Unitaid also supports regional manufacturing initiatives (MADE, MedSuRe Africa) to strengthen Africa's health product supply chains.

Differentiator

Problem solved

Functional benefit

Products and services

  • MADE Program (Market Access and Diagnostic Equity) Unitaid-funded program that supports African manufacturers in developing and scaling diagnostic test production for regional and global markets, addressing the 70% of pharmaceuticals consumed in Africa that are imported.
  • MedSuRe Africa Program Unitaid-funded program led by US Pharmacopeia (USP) that boosts regional production of essential medicines (including HIV, malaria, and postpartum hemorrhage treatments) and related quality testing infrastructure in Africa.
  • Antimalarial Drug Resistance Initiative A US$26.5 million Unitaid-funded initiative led with Jhpiego to curb rising antimalarial drug resistance in Africa.
  • Cervical Cancer Elimination Call for Proposals (Secondary Prevention) Unitaid funding call worth up to US$50 million for projects accelerating cervical cancer elimination through secondary prevention (screening and pre-cancer treatment) in low- and middle-income countries.
  • Climate-Proof Health Products Funding Opportunity A US$10 million Unitaid funding opportunity to generate evidence on how extreme heat and humidity affect the safety, quality and effectiveness of essential medicines and health products in LMICs.
  • Pregnant Women's Care Expansion Initiative A US$52 million Unitaid investment to expand lifesaving care for pregnant women in Africa.

Quantifiable outcome

  • 390 million people benefit annually from Unitaid-supported health products
  • +5 more outcomes

Companies that use Unitaid

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Unitaid technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Unitaid partnerships and signals

Strategic signal

Partnerships

18 partnerships are on record, tiered core, supporting and flagship.

  • Elton John AIDS FoundationcoreStrategic or Co-development Partner · 13 May 2026Unitaid and Elton John AIDS Foundation advocating for urgent scale-up of lenacapavir for adolescent girls and young women in sub-Saharan Africa. Organizations secured ceiling price of approximately £30 per person per year for quality-assured generic versions.
  • Clinton Health Access Initiative (CHAI)coreStrategic or Co-development Partner · 12 March 2026Unitaid, CHAI, and Wits RHI coordinated with Dr. Reddy's Laboratories to supply generic lenacapavir at $40 per person annually for 120 LMICs. Proof that early market-shaping can make affordability keep pace with innovation.
  • Wits RHIcoreStrategic or Co-development Partner · 12 March 2026Wits RHI collaborated with Unitaid and CHAI to coordinate lenacapavir generic pricing agreement with Dr. Reddy's Laboratories for 120 low- and middle-income countries.
  • FiocruzcoreStrategic or Co-development Partner · 5 March 2026South Africa negotiating voluntary license agreement with Gilead Sciences with support from Unitaid and US Pharmacopeia. Lenacapavir use kicked off in South Africa and Brazil through Unitaid partnership with Wits RHI and Fiocruz.
  • FINDcoreImplementation/ SI/ Consulting Partner · 26 February 2026Unitaid invested US$44 million since 2022 to advance TB diagnostics through partnerships with LSTM and FIND. Multi-country trial demonstrated pooled testing reducing TB testing costs by up to 65%.
  • Liverpool School of Tropical Medicine (LSTM)coreImplementation/ SI/ Consulting Partner · 26 February 2026Unitaid partnership with LSTM supporting TB diagnostics advancement as part of US$44 million investment since 2022.
  • Noul Co. LtdsupportingStrategic or Co-development Partner · 6 January 2026Noul debuted AI-powered cervical cancer diagnostic solution miLab CER at CES 2026. Unitaid recommended miLab CER for use in 2024 alongside solutions from Roche and Hologic.
  • Accesso BiotechsupportingStrategic or Co-development Partner · 18 December 2025Support from Gates Foundation, Unitaid, and CHAI to expand manufacturing and global access to VITA CD4 test for managing advanced HIV disease. Initiative aims to accelerate regulatory approval and scale production.
  • Dr. Reddy's LaboratoriescoreStrategic or Co-development Partner · 22 November 2025Indian pharmaceutical company plan to produce generic versions of lenacapavir for $40 a year starting in 2027. Supported by Unitaid, Clinton Health Access Initiative, and Wits RHI to expand competitive generics ecosystem for the drug.
  • Hetero LabscoreStrategic or Co-development Partner · 24 September 2025Gates Foundation partnership with Indian manufacturer Hetero Labs to produce low-cost generic version of lenacapavir at roughly $40 per patient per year, pending regulatory approval expected as early as 2027. Part of broader effort to accelerate affordable access to lenacapavir in LMICs.
  • PATHflagshipImplementation/ SI/ Consulting Partner · 21 August 2025PATH leads MADE program receiving US$ 11 million to support African companies in developing and scaling diagnostic test production for regional and global markets. Part of US$ 50 million flagship programs to strengthen Africa's regional manufacturing.
  • US Pharmacopeia (USP)flagshipImplementation/ SI/ Consulting Partner · 21 August 2025USP leads MedSuRe Africa program receiving US$ 35.5 million to boost production of essential medicines including HIV, malaria, and postpartum hemorrhage treatments along with related quality testing infrastructure.
  • Medicines Patent PoolsupportingStrategic or Co-development Partner · 21 August 2025Medicines Patent Pool receives US$ 1.5 million for complementary work supporting the MedSuRe Africa flagship program for regional manufacturing.
  • JhpiegocoreImplementation/ SI/ Consulting Partner · 21 August 2025Unitaid and Jhpiego launch US$26.5 million initiative to curb rising antimalarial drug resistance in Africa.
  • PoskomcoreStrategic or Co-development Partner · 20 May 2025Unitaid and CHAI announced new pricing agreement with South Korean company Poskom to dramatically lower cost of AirRay 20 ultraportable digital chest x-ray system, making it available at discounted price to 138 LMICs.
  • Japan / NikkisosupportingStrategic or Co-development Partner · 1 January 2025Unitaid and Japan's Nikkiso partner with Kenya and Tanzania to build liquid medical oxygen facilities in East Africa through project with Japanese government committing funds.
  • World Health Organization (WHO)coreStrategic or Co-development Partner · 1 January 2006Unitaid is a hosted partnership of WHO. Credibility and insight through WHO hosting. Operations administered in accordance with Unitaid's constitution and WHO rules. WHO uses evidence from Unitaid investments to create policy and guidance.
  • The Global FundcoreChannel Partner/ Reseller/ Distributor · 1 January 2006Collaboration with Global Fund to take products and best practices to scale. Global Fund is a major scale-up partner for Unitaid-supported interventions.

Scale indicators17 records

Recent moves7 records

Expansion highlights7 records

Unitaid competitors and assessment

Company assessment

Direct peers

  • Gavi, the Vaccine Alliance: Multilateral public-private partnership accelerating vaccine access in LMICs through innovative financing, market shaping, and Gavi-Advanced Market Commitments. Same financing/partnership DNA as Unitaid but focused on immunization.
  • Medicines for Malaria Venture (MMV): Public-private partnership developing and delivering malaria treatments. Shares Unitaid's grant-funded, market-shaping approach and operates within the same global health ecosystem with overlapping donor and partner networks.
  • PATH: Leads Unitaid's $11M MADE program for African diagnostic manufacturing and is a longstanding implementing partner across Unitaid's investment portfolio. Overlapping mission of accelerating health innovation in LMICs.
  • Drugs for Neglected Diseases initiative (DNDi): Not-for-profit R&D organization developing treatments for neglected diseases (sleeping sickness, leishmaniasis, Chagas disease, etc.) with funding from public and philanthropic donors. Closely mirrors Unitaid's grant-funded, partnership-driven model for access-oriented health R&D.
  • Clinton Health Access Initiative (CHAI): Operates as Unitaid's direct implementation co-pilot on market-shaping deals (lenacapavir generic pricing for 120 LMICs, AirRay 20 X-ray pricing for 138 LMICs). Both organizations negotiate volume guarantees and pooled procurement across the same disease portfolio.
  • FIND (Foundation for Innovative New Diagnostics): Strategic implementation partner for Unitaid's TB diagnostics portfolio ($44M joint investment since 2022) and pooled testing trials. Both organizations focus on introducing diagnostic innovations to LMIC public health systems.
  • The Global Fund to Fight AIDS, Tuberculosis and Malaria: Multilateral financing mechanism for the same three diseases Unitaid targets (HIV, TB, malaria), serving as Unitaid's primary scale-up partner to take innovative health products to LMICs. Operates with similar donor-funded, partnership-based model.
  • Medicines Patent Pool: Founded by Unitaid in 2010 and still receiving direct Unitaid funding ($1.5M for MedSuRe Africa). MPP negotiates voluntary licenses for HIV, TB, and hepatitis C medicines in LMICs — a core enabler of Unitaid's generic pricing strategy.
  • TB Alliance: Non-profit product development partnership advancing faster, cheaper TB regimens, working closely with Unitaid as a co-funder and implementer of TB innovations in LMICs.

Others

  • Wellcome Trust: Major philanthropic funder of global health R&D and a current Unitaid donor. While not a direct competitor, Wellcome shapes the same funding and policy ecosystem and increasingly co-invests on issues like pandemic preparedness and climate-health.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Unitaid social profiles

Digital presence

Unitaid financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Unitaid leadership team

Management profile

Number of profiles

Profiles7 records

Unitaid funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Unitaid M&A and investment

M&A and investment

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unitaid

What does Unitaid do?

Unitaid finances and accelerates the development, introduction, and scale-up of innovative health products for HIV, tuberculosis, malaria, women's and children's health, and pandemic preparedness in low- and middle-income countries. It does this primarily through grants to implementing partners and market-shaping agreements (volume guarantees, ceiling prices, and technology partnerships) that drive down product costs and accelerate access for the people who need them most.

Is Unitaid a public or private company?

Unitaid is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Unitaid founded?

Unitaid was founded in 2006. It employs 101 to 250 people.

Where is Unitaid based?

Unitaid is headquartered in Le Grand-saconnex, Switzerland, in the Europe region.

How does Unitaid make money?

Two revenue lines are on record. Grants and Donations are the primary driver. The others are innovative Financing.

Who are Unitaid's main competitors?

Direct peers on record are Gavi, the Vaccine Alliance, Medicines for Malaria Venture (MMV), PATH, Drugs for Neglected Diseases initiative (DNDi), Clinton Health Access Initiative (CHAI), FIND (Foundation for Innovative New Diagnostics), The Global Fund to Fight AIDS, Tuberculosis and Malaria, Medicines Patent Pool and TB Alliance. Wellcome Trust is listed as an others.

Does Unitaid have an API?

No public API is recorded for Unitaid.

What industry is Unitaid in?

Unitaid's product category is Global Health Financing and Market Shaping. Its primary akta.pro industry code is HLAJAKAC, Global Health Financing Mechanisms, with a secondary code of HLAJAKAA, Multilateral Global Health Agencies (UN/IFIs). Its NAICS code is 813212 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The IndependentThe world’s medicines were made for a climate that no longer existsUnitaid launched the SHIELD project to study how rising temperatures affect essential medicines, including oxytocin used in childbirth. Heat-stable carbetocin can replace refrigerated oxytocin, and the £8 million initiative will measure heat exposure from port to patient. The project aims to protect medicines for women in heat-affected areas.AllafricaAfrica: Celebrating Two Decades of Leadership and Service - a Tribute to Dr. Philippe DunetonUnitaid's Executive Board congratulated Dr. Philippe Duneton on his upcoming retirement after two decades of service. His leadership helped build Unitaid into a leading catalytic health organization, advancing access to medicines and diagnostics for millions. The Board expressed gratitude and noted his legacy will guide the organization under new Executive Director Luis Pizarro.AllafricaAfrica: New Unitaid Report Charts a Path to Expand Access to Lifesaving Newborn CareUnitaid released a new report on small and sick newborn care ahead of World Prematurity Day, highlighting opportunities to expand access to medicines, diagnostics, and devices. The report notes that small and sick newborns account for over half of the 2.3 million newborn deaths annually, with the greatest burden in low- and middle-income countries.Business & FinancialUnitaid Launches USD 10.9M Initiative To Protect Essential Health Products From Rising TemperaturesUnitaid launched a $10.9M initiative led by USP to study heat and humidity risks to essential health products. The SHIELD project runs 2027-2030, testing products in India, Kenya, Nigeria, and Senegal, with findings validated in Brazil and South Africa. Results will guide packaging, storage, and regulatory practices for climate-resilient health delivery.Business & FinancialPAHO Secures First-Ever Region-Wide Access Agreements For HPV Testing Across Latin America And The Caribbean, With Support From UnitaidPAHO secured first-ever region-wide access agreements for HPV testing across Latin America and the Caribbean, with Unitaid support. Participating countries expect cost savings of 30-70 percent, and the agreements include implementation support and training. The initiative aims to advance WHO's 90-70-90 cervical cancer elimination targets.AllafricaNigeria: Cheap Version of Breakthrough HIV Prevention Shot ApprovedThe US FDA approved a low-cost generic version of lenacapavir, a twice-yearly HIV prevention shot, announced by Dr Reddy's Laboratories and Unitaid. The drug will cost $40 per person per year in 120 countries under a 2025 pricing agreement. Lenacapavir was first approved in June 2025 after showing over 99.9% effectiveness in trials.ExamePrimeiro genérico para prevenir HIV é aprovado nos EUA; entenda como funcionaThe US FDA granted provisional approval to the first generic version of lenacapavir, an injectable HIV PrEP, on Tuesday. The drug costs $40 per person annually under a licensing agreement with Unitaid and others, compared to $28,000 for the original. The approval is provisional and does not guarantee US market access.Naver"韓 AI·진단 기술, 저소득국 보건격차 줄이고 새시장 열 기회"Unitaid chair Ancler Anfray said Korea's AI and diagnostic technology can help low-income countries, citing Korea's $22 million 2024 contribution. He highlighted partnerships with Foscom and Biogen, and urged investment in diagnostics to prepare for the next pandemic.MedicalxpressUS approves cheap generic of breakthrough HIV shot for poorer countriesThe U.S. FDA tentatively approved a low-cost generic of lenacapavir, a twice-yearly HIV prevention shot, for 120 countries at $40 per person per year. The Indian maker Dr. Reddy's and Unitaid announced the approval, which follows Gilead's voluntary licenses to generic manufacturers. Unitaid is working with governments to support country-led rollouts.Punch NewspapersUS approves cheap version of HIV prevention shotThe US FDA tentatively approved a low-cost generic version of lenacapavir, a twice-yearly HIV prevention shot, at $40 per person per year in 120 countries. The approval, announced by Dr. Reddy's Laboratories and Unitaid, brings the drug closer to market in low-income countries. Unitaid is working with governments to support country-led rollouts.